Adagio Medical Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Adagio Medical Holdings, Inc. (ADGM) on May 21, 2026. The company is an emerging growth company incorporated in Delaware and trades on The Nasdaq Stock Market LLC. The report addresses a significant corporate event under Item 8.01 (Other Events).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory milestone and does not contain financial statements or performance data.
Material Changes
The material event reported is the submission of a Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the company's vCLAS® Ventricular Ablation System. This system is intended for the treatment of Ventricular Tachycardia.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the PMA submission. The filing does not provide specific financial guidance, future outlook projections, or a detailed discussion of risks and contingencies beyond the inherent uncertainties of the FDA approval process. No unusual items were disclosed in this specific filing.
Investor Verification Checklist
- Verify the status of the vCLAS® Ventricular Ablation System PMA application with the FDA.
- Review the full text of the press release attached as Exhibit 99.1 for additional clinical or regulatory details.
- Monitor subsequent filings for updates on the FDA review timeline or potential requests for additional information.
- Check the company's latest 10-K or 10-Q for current financial health and liquidity status, as this 8-K does not contain such data.